US Market News
1月前
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with CardiomyopathyApril 27, 2026 4:05 PM
Business Wire
Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3
Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 CLEOPATTRA clinical trial in ~1280 participants with ATTR-CM; primary completion expected in 2029
The Fast Track Designation underscores the unmet need within ATTR-CM and could expedite the review of coramitug
Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter antibody currently in Phase 3 development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Fast Track Designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and fill an unmet medical need.
“We are encouraged by Novo Nordisk’s receipt of Fast Track Designation for coramitug, which underscores their continued commitment to advancing coramitug for patients living with ATTR-CM,” said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena.
“We are pleased that the FDA has granted Fast Track Designation for coramitug, a recognition that reflects both the seriousness of ATTR-CM and the significant unmet need that remains for people living with this life-threatening disease, despite standard of care,” said Michelle Lim-Watson, Associate Portfolio Vice President, Cardiovascular Disease and Rare Diseases, U.S. R&D, Novo Nordisk. “Coramitug is currently being investigated in the ongoing Phase 3 CLEOPATTRA trial, which we believe could mark a meaningful step forward in how we treat ATTR-CM in the future.”
ATTR-CM is a progressive disease caused by the deposition of transthyretin as amyloid in the myocardium. Current therapies may slow disease progression but do not clear existing deposits. Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid through antibody-mediated phagocytosis4.
Novo Nordisk is evaluating coramitug in the ongoing Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM with primary completion expected in 2029 (NCT07207811).
Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021. Under the terms of the acquisition agreement, Prothena is eligible to receive up to $1.2 billion including an upfront payment and upon achievement of clinical development and sales milestones, with $150 million earned to date.
About Coramitug (PRX004)
Coramitug is an investigational antibody designed to deplete amyloid associated with disease pathology in hereditary and wild type ATTR amyloidosis, without affecting the native, normal tetrameric form of the protein1-3. Coramitug’s proposed mechanism of action is to deplete both the deposited amyloid to improve organ function and circulating non-native TTR to prevent further organ deposition1-3. This differentiated depleter mechanism of action could be developed as a monotherapy approach to ATTR amyloidosis and might also complement existing therapeutic approaches which either stabilize or reduce production of the native TTR tetramer3.
In a Phase 2 clinical trial conducted by Novo Nordisk, coramitug 60 mg/kg significantly reduced and improved NT-proBNP from baseline, in a patient population in which the vast majority (>80%) were already receiving standard of care treatment for ATTR-CM. Furthermore, compared with placebo, coramitug was associated with improvements in multiple echocardiographic parameters of cardiac function, and was well-tolerated in participants with ATTR-CM. These findings support the potential of coramitug as an amyloid-clearing immunotherapy for ATTR-CM and provide a rationale for additional clinical investigation of coramitug for the treatment of patients with ATTR-CM4.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, design, and proposed mechanism of action coramitug; plans for ongoing and future clinical trials of coramitug; and amounts we might receive under our agreement with Novo Nordisk. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
References:
1 Preclinical studies of PRX004 (coramitug) – data on file
2 Higaki JN et al. Amyloid, 2016
3 Suhr OB et al. Amyloid, 2025
4 Fontana M et al. Circulation, 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20260427325583/en/
Mark Johnson, CFA
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
IR@prothena.com
Media@prothena.com
Original: Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
US Market News
2月前
Prothena Announces Leadership Team UpdatesApril 10, 2026 4:05 PM
Business Wire
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced updates to its leadership team. Annie Kingston is being promoted to Chief Strategy Officer and Michael Isaacs is being promoted to General Counsel and Corporate Secretary. Mr. Isaacs succeeds Michael Malecek who will be departing from Prothena. Ms. Kingston and Mr. Isaacs will join Prothena’s leadership team and will report to Gene Kinney, Ph.D., President and Chief Executive Officer. Ms. Kingston’s promotion is effective immediately and Mr. Isaacs’ promotion will take effect following Mr. Malecek’s departure in June.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260410894357/en/Annie Kingston, Prothena
Ms. Kingston will lead the Company’s growth strategy aimed at driving sustainable value creation and Mr. Isaacs will be the Company’s most senior legal officer, overseeing the corporate legal function. Tran Nguyen, who previously served as Chief Financial Officer and Chief Strategy Officer, continues to serve as the Company’s Chief Financial Officer.
“Prothena is focused on supporting our partnered clinical programs, investing in our wholly-owned preclinical programs and technology, and exploring research collaborations and licensing partnerships to further drive our mission,” said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. “Annie has played a key role supporting Prothena’s evolving corporate strategy and I am excited to expand her current responsibilities to further elucidate the potential of our preclinical programs and CYTOPE® technology. On behalf of our Board and all Prothenians, I would like to thank Mike Malecek for his leadership over the past seven years, as well as his succession planning leading to the seamless transition to Mike Isaacs. I look forward to continuing to work with Mike Isaacs in his new role leading our corporate legal functions. Having already made significant contributions to the Company, both Annie and Mike are well positioned to step into their expanded roles. I am delighted to continue to work closely with them, our Board, and the rest of the leadership team as we execute our long-term strategy.”
Executive Biographies
Ms. Kingston joined Prothena in 2023, serving most recently as Vice President, Corporate Strategy and Chief of Staff. Prior to joining Prothena, Ms. Kingston was an Associate Principal and Project Leader at ClearView Healthcare Partners (a life sciences strategy consultancy), where she advised pharmaceutical and biotechnology companies on both product-level and corporate strategy from 2017 to 2023. Prior to that role, she was a consultant at The Dedham Group. She earned her B.A. in Biology and Psychology from Fairfield University.
Mr. Isaacs joined Prothena in 2020, serving most recently as Deputy General Counsel. Prior to joining Prothena, he was a Corporate Associate at Arnold & Porter Kaye Scholer LLP from 2015 to 2020. Prior to entering the legal profession, he held multiple research positions, including at the Salk Institute for Biological Studies and Biogen Idec. Mr. Isaacs earned his B.S. in Biology (Microbiology) and his M.S. in Biology (Biochemistry and Biophysics) both from the University of California, San Diego, and his J.D. from Santa Clara University School of Law.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the continued advancement of our preclinical and clinical pipeline, including the potential and advancement of CYTOPE. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, as well as those described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260410894357/en/
Mark Johnson, CFA
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
IR@prothena.com
Media@prothena.com
Original: Prothena Announces Leadership Team Updates
US Market News
3月前
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026March 21, 2026 4:05 PM
Business Wire
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations on clinical updates from prasinezumab for the treatment of Parkinson’s disease and BMS-986446 for the treatment of Alzheimer’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark, and online.
Roche Presentations on Prasinezumab for the Potential Treatment of Parkinson’s Disease
Industry Symposium – Pathways to Progress: Exploring Innovations in AD and PD for Future Practice
Chair: Malú G. Tansey, Ph.D., Indiana University School of Medicine Stark Neuroscience Institute
Date: Tuesday March 17, 2026
This symposium reviewed the evolving understanding of the molecular pathophysiology and disease heterogeneity across Alzheimer's disease (AD) and Parkinson's disease (PD). Explored current and emerging treatment pathways, e.g. alpha-synuclein, amyloid-beta and neuroinflammation; including diagnostics, biomarkers and therapeutics. Considered how the advancing understanding of AD and PD informs innovative clinical development approaches and clinical practice.
Oral Presentation – Modeling Parkinson’s Disease Progression to Quantify Long-Term Treatment Effects via the Concept of ‘Time Saved’
Presenter: Benjamin Ribba, Roche
Date: Thursday March 19, 2026
The comparison of PASADENA open-label extension (OLE) data with PPMI-based model predictions supports potential disease-modifying efficacy with an estimated two years of ‘time saved’ providing an intuitive measure of long-term benefit. The observed PASADENA OLE outcomes consistently deviated from the model-predicted progression, suggesting a sustained treatment effect. On average, participants were approximately two years less advanced in disease severity five years after the start of the trial compared to the virtual comparator.
Oral Presentation – Prasinezumab in Early-Stage Parkinson’s Disease: Additional Data from the PADOVA Study
Presenter: Tania Nikolcheva, M.D., Ph.D., Roche
Date: Saturday March 21, 2026
Longer term data from the PADOVA OLE study in early-stage PD showed a sustained effect of prasinezumab in slowing Parkinson’s progression on top of effective symptomatic therapies. The totality of the evidence suggests a possible clinical benefit of prasinezumab and informed the initiation of the Phase III PARAISO study.
Poster Presentation – Prasinezumab’s Impact on Neuromelanin- and Iron-Sensitive MRI Biomarkers in Parkinson’s Disease: Findings from the PADOVA Phase IIb Study
Exploratory biomarker analysis of PADOVA suggests that prasinezumab is biologically active. This is supported by imaging biomarkers crucial to PD pathology, showing a slowing in the progressive loss of neuromelanin signal in substania nigra pars compacta and reduced iron accumulation in the putamen.
Poster Presentation – Sustained Effect on Prasinezumab on Parkinson’s Disease Motor Progression in the Open-Label Extension of the PASADENA Trial, 5-Year Update
At Year 5, the combined PASADENA arm (delayed- and early-start groups) showed less disease progression compared to the PPMI cohort. This lower progression was observed across multiple measures.
Poster Presentation – Digital Health Technology Detects Group Differences in Practically-Defined OFF L-DOPA State: Results of PADOVA Phase IIb Study of Prasinezumab
Post-hoc Digital Health Technology analyses showed consistent trends favoring prasinezumab in digital data collected in the practically-defined OFF L-DOPA state, in line with the PASADENA Phase 2a Simple Sum digital finding and clinical PADOVA readout.
Bristol Myers Squibb Presentation on BMS-986446 for the Potential Treatment of Alzheimer’s Disease
Oral Presentation – Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BMS-986446 in Healthy Participants, Including Those of Japanese Ethnicity
Presenter: Ilena George, M.D., Bristol Myers Squibb
Date: Saturday March 21, 2026
Single-dose BMS-986446 was safe and well tolerated in all participants, including those of Japanese ethnicity. Plasma exposure of BMS-986446 increased dose proportionally. No anti-drug antibodies were detected. These results support BMS-986446 dosing in ongoing clinical studies without adjustments for Japanese ethnicity.
About Prasinezumab
Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease.
About Parkinson’s Disease
Parkinson’s disease is a chronic, progressive and debilitating neurodegenerative disease characterized by the gradual loss of neurons that make dopamine and other nerve cells. Today, Parkinson’s disease affects over 10 million people worldwide. The prevalence of Parkinson’s disease is increasing, and it has become one of the fastest-growing neurological disorders. Currently, symptomatic treatments that effectively alleviate motor symptoms are available. However, no therapies slow down or stop the clinical progression of Parkinson’s disease.
About BMS-986446
BMS-986446 is a humanized monoclonal antibody that targets multiple domains of the microtubule binding region of tau, a highly pathogenic tau fragment associated with neurofibrillary tangle formation and cognitive decline in Alzheimer’s disease. BMS-986446 binds to specific regions of the tau protein (R1–R3 within the microtubule-binding domain) to stop cell-to-cell spread of tau and tau uptake into cells. It also activates microglia—the brain’s immune cells—through its Fc receptor function, promoting the clearance of tau via phagocytosis.
About Alzheimer’s Disease
Alzheimer’s disease is a progressive, multifaceted and devastating neurodegenerative disease and the most common type of dementia in adults. Changes in the brain disrupt communication between neurons, impacting memory, cognition and behavior. As a result, Alzheimer’s disease has a significant impact on the day-to-day lives of those it directly affects, as well as on their families, caregivers and friends, resulting in considerable shifts in interpersonal relationships. There remains a critical need for disease-modifying therapies that can slow or delay the progression of Alzheimer’s disease as well as therapies that manage and ease neurobehavioral symptoms.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific macromolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, designs, proposed mechanisms of action, and potential administration of prasinezumab and BMS-986446; and the continued advancement of our preclinical and clinical pipeline, including the potential and advancement of CYTOPE. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, as well as those described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260321254343/en/
Mark Johnson, CFA
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
IR@prothena.com
Media@prothena.com
Original: Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
US Market News
3月前
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with CardiomyopathyMarch 9, 2026 4:05 PM
Business Wire
Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3
Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nordisk
Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial evaluating coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Novo Nordisk is evaluating coramitug in the ongoing Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM with primary completion expected in 2029 (NCT07207811).
Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021. Under the terms of the acquisition agreement, Prothena is eligible to receive up to $1.2 billion upon achievement of clinical development and sales milestones, including $150 million earned to date.
About Coramitug (formerly PRX004)
Coramitug (formerly PRX004) is an investigational antibody designed to deplete amyloid associated with disease pathology in hereditary and wild type ATTR amyloidosis, without affecting the native, normal tetrameric form of the protein1-3. Coramitug’s proposed mechanism of action is to deplete both the deposited amyloid to improve organ function and circulating non-native TTR to prevent further organ deposition1-3. This differentiated depleter mechanism of action could be developed as a monotherapy approach to ATTR amyloidosis and might also complement existing therapeutic approaches which either stabilize or reduce production of the native TTR tetramer3.
In a Phase 2 clinical trial conducted by Novo Nordisk, coramitug 60 mg/kg significantly reduced NT-proBNP in a patient population predominantly in which the vast majority (>80%) were already receiving standard of care treatment for ATTR-CM. Furthermore, compared with placebo, coramitug was associated with improvements in multiple echocardiographic parameters of cardiac function, and was well-tolerated in participants with ATTR-CM. These findings support the potential of coramitug as an amyloid-clearing immunotherapy for ATTR-CM and provide a rationale for additional clinical investigation of coramitug for the treatment of patients with ATTR-CM4.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, design, and proposed mechanism of action coramitug; plans for ongoing and future clinical trials of coramitug; and amounts we might receive under our agreement with Novo Nordisk. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
References:
1 Preclinical studies of PRX004 (coramitug) – data on file
2 Higaki JN et al. Amyloid, 2016
3 Suhr OB et al. Amyloid, 2025
4 Fontana M et al. Circulation, 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20260309588944/en/
Mark Johnson, CFA
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
IR@prothena.com
Media@prothena.com
Original: Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
US Market News
3月前
Prothena Announces up to $100 Million Share Repurchase PlanFebruary 27, 2026 4:15 PM
Business Wire
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized a Share Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company’s outstanding ordinary shares, par value $0.01 per share.
Prothena had cash, cash equivalents and restricted cash of $308.4 million and no debt as of December 31, 2025. Excluding any potential purchases under this Share Repurchase Plan, Prothena expects to end the year with approximately $255 million in cash, cash equivalents, and restricted cash. This financial guidance does not include the potential to earn up to $105 million of aggregate clinical milestone payments from strategic partners in 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb.
Prothena may repurchase the shares from time to time in open market transactions, which may be structured to occur in accordance with the requirements of Rule 10b-18 of the Securities Exchange Act of 1934, as amended. Prothena may also enter into Rule 10b5-1 plans to facilitate repurchases. The timing, number of shares repurchased, and prices paid for the shares under this program will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing share prices, and other considerations. The Share Repurchase Plan will expire on December 31, 2026, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of ordinary shares. No amount or any amount of outstanding ordinary shares may be acquired by the expiration of the Share Repurchase Plan, at Prothena’s sole discretion.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, our plans and expectations regarding the Share Repurchase Plan, capital allocation, and other objectives and expectations; our anticipated cash burn and projected year end cash, cash equivalents, and restricted cash; and the receipt of clinical milestone payments in 2026. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to uncertainties related to the completion of operational and financial closing procedures, audit adjustments and other developments that may arise that would require adjustments to the preliminary financial results included in this press release, as well as those described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260227690121/en/
Mark Johnson, CFA, Vice President, Investor Relations
650-837-8550
IR@prothena.com
Media@prothena.com
Original: Prothena Announces up to $100 Million Share Repurchase Plan
stocktrademan
11年前
$PRTA recent news/filings
bullish
## source: finance.yahoo.com
Fri, 29 May 2015 13:25:27 GMT ~ Prothena Shares Initiated With Buy At UBS
read full: http://finance.yahoo.com/news/prothena-shares-initiated-buy-ubs-132527070.html
*********************************************************
Tue, 26 May 2015 23:05:01 GMT ~ Lightning Round: Great spec for 2nd half of 2015
read full: http://www.cnbc.com/id/102707966?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=102707966
*********************************************************
Fri, 22 May 2015 18:18:41 GMT ~ PROTHENA CORP PLC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
read full: http://biz.yahoo.com/e/150522/prta8-k.html
*********************************************************
Thu, 21 May 2015 12:16:38 GMT ~ Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results at 20th Congress of the European Hematology Association
[at noodls] - DUBLIN, Ireland, May 21, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel ...
read full: http://www.noodls.com/view/FC8F922DE1BB00D899DBCC30C082FDDDE8451D4A
*********************************************************
Thu, 21 May 2015 12:01:01 GMT ~ Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results at 20th Congress of the European Hematology Association
[GlobeNewswire] - DUBLIN, Ireland, May 21, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel ...
read full: http://finance.yahoo.com/news/prothena-announces-presentation-clinical-data-120101865.html
*********************************************************
$PRTA charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PRTA company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PRTA/company-info
Ticker: $PRTA
OTC Market Place: Not Available
CIK code: not found
Company name: Prothena Corp plc
Incorporated In:
Business Description:
$PRTA share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$PRTA extra dd links
Company name: Prothena Corp plc
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PRTA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PRTA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PRTA+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PRTA/news - http://finance.yahoo.com/q/h?s=PRTA+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PRTA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PRTA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PRTA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PRTA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Prothena+Corp+plc&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Prothena+Corp+plc
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Prothena+Corp+plc&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PRTA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PRTA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PRTA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PRTA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PRTA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PRTA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PRTA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PRTA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PRTA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PRTA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PRTA+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PRTA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PRTA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PRTA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PRTA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PRTA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PRTA/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PRTA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PRTA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PRTA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PRTA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PRTA
$PRTA DD Notes ~ http://www.ddnotesmaker.com/PRTA
KingDMC
11年前
Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares
Source: GlobeNewswire Inc.
Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that it priced an underwritten public offering of 3,300,000 of its ordinary shares at a price to the public of $37.00 per ordinary share, before the underwriting discount. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 495,000 of its ordinary shares.
Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $114.2 million, after deducting the underwriting discount and estimated offering expenses, but excluding any exercise of the underwriters' option to purchase additional ordinary shares. The offering is expected to close on April 13, 2015, subject to customary closing conditions.
Credit Suisse, RBC Capital Markets and UBS Investment Bank are acting as joint book-running managers, and Oppenheimer & Co., Wedbush PacGrow, Ladenburg Thalmann and LifeSci Capital are acting as co-managers for the offering.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Monksdream
2年前
whytestocks
6年前
ClayTrader
6年前
PennyStock Alert
7年前
FairviewInvestor
8年前
MinnieM
8年前
ValueInvestor15
9年前
crudeoil24
11年前
メールアドレスで登録
